Moderna to Request FDA EUA for COVID-19 Vaccine for Young Children
This week, Moderna announced it plans over the coming weeks to submit an emergency use authorization (EUA) request to the U.S. Food and Drug Administration (FDA) for a two-dose COVID-19 mRNA vaccine for children six months to six years old.
The vaccine for children is a quarter of the dose of Moderna’s adult COVID-19 vaccine and the two-dose regimen was found to generate similar protection against the virus as it did for adults. Real-life effectiveness was less robust during the omicron wave, but no children were found to develop severe disease. Reported side effects were similar in children as adults, with no one in the clinical trial developing severe side effects.
Additional information is available here.